Destiny Pharma hailed 'positive' results from an independent study showing that the company's drug to combat antimicrobial resistance had met its primary objective. In addition to the study reporting a favourable safety and local tolerability profile of the nasal gel formulation (the primary objective), the study also noted, as expected, that exposure to company's antimicrobial resistance drug, XF-73, produced a rapid reduction in levels of nasal S. aureus in all patients included in the trial, the company said. The clinical stud underscores 'our confidence in the potential of XF-73 as a novel treatment to prevent the occurrence of post-surgical S. aureus bacterial infections,' Destiny said. 'We look forward to reporting headline data in mid-2020 from our ongoing 200 patient phase 2b trial that is assessing the ability of XF-73 to reduce nasal levels of S. aureus in patients at high risk of infection that are undergoing surgery,' it added. At 8:58am: (LON:DEST) Destiny Pharma Plc share price was +1.5p at 41.5p
Sign up to our
Subscribe to the latest investing news by entering your email address below
You can opt out at any time.
For five days a week you will get
- The latest company news
- Insight into investment trends
- Round-up of director's buys and sells
- Articles from Shares magazine
Plus more useful investment content and occasional promotional offers.
UK 350 Risers and Fallers
Tweets not available.